]>
IRCT20180412039283N1 IRCT 2021-02-16 Shahid Beheshti University of Medical Sciences Investigation Effect of losartan NAFLD patients : Investigation Effect of losartan on improving liver function testes in NAFLD patients ( Non Alcoholic Fatty Liver Disease) 2017-12-02 anticipated 250 Complete https://irct.ir/trial/45843 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: We used block randomization method.each block size was 2 by 2, and in total 16 blocks were considered.the sequences for packages within each block were:AABB_BBAA_ABBA_BAAB_ABAB_BABA .then each were marked from 1 to 6 as above.After that the packages within blocks were sequentially numbered from 1 to 64, Blinding description: The sample recipient and patient are not aware of the type of drug.the lab that received samples isn't aware of type of drug. losartan and placebo are same shape.and they pack same. 3 NAFLD. Intervention 1: Intervention group: losartan 25 mg twice a day for 12 weeks. Intervention 2: Control group: placebo 25 mg twice aday for 12 weeks. Yes - There is a plan to make this available What will be shared: All data is shared after unidentifiable people When: 6 months after printing the results To whom: Researchers working in academic institutions Conditions: Use data to compare with other similar interventions Where to obtain: Aylar fazlzadeh dr.aylar.fazlzadeh@gmail.com How to obtain: email request Comments:
public Meghdad Sedaghat
Rasul_e Akram hospital, Mansuri Street, Sattarkhan Street
Tehran Iran (Islamic Republic of) 1324569871 +98 21 6435 1000 sedaghat@sbmu.ac.ir Shahid Beheshti University of Medical Sciences scientific Meghdad Sedaghat
Rasul_ e Akram hospital, Mansuri Street, Sattarkhan Street
Tehran Iran (Islamic Republic of) 1324569871 +98 21 6435 1000 sedaghat@sbmu.ac.ir Shahid Beheshti University of Medical Sciences Iran (Islamic Republic of) patients with pre hypertension and fatty liver 20 years 80 years Both history of other liver diseases except fatty liver K76.0 Fatty (change of) liver, not elsewhere classified Treatment - Drugs Placebo Intervention group: losartan 25 mg twice a day for 12 weeks Control group: placebo 25 mg twice aday for 12 weeks Liver functions tests. Timepoint: liver function tests before losartan and 12 weeks after losartan. Method of measurement: laboratory. Shahid Beheshti University of Medical Sciences Approved 2019-02-09 Ethics committee of Shahid Beheshti University of Medical Sciences koodakyari street.velenjak Tehran Tehran Iran (Islamic Republic of)